Adagene Inc., a Suzhou antibody discovery and engineering company, closed an $8 million Series A round of financing with participation by two Fidelity funds -- Fidelity Biosciences and Fidelity Asia Growth -- along with the WuXi Venture Fund, the investment arm of WuXi PharmaTech (NYSE: WX) (see story). Adagene partners with other pharmas to develop antibodies for the partners’ needs and is also building its own portfolio of products, which it will out-license later in their development.
Help employers find you! Check out all the jobs and post your resume.
